🇺🇸 FDA
Patent

US 8709417

Combination immunotherapy for the treatment of cancer

granted A61KA61K2039/505A61K2039/507

Quick answer

US patent 8709417 (Combination immunotherapy for the treatment of cancer) held by BOARD OF REGENTS expires Mon Apr 24 2034 00:00:00 GMT+0000 (Coordinated Universal Time). Status: granted.

Key facts

Applicant
BOARD OF REGENTS
Grant date
Tue Apr 29 2014 00:00:00 GMT+0000 (Coordinated Universal Time)
Expiration
Mon Apr 24 2034 00:00:00 GMT+0000 (Coordinated Universal Time)
Claims
6
CPC classes
A61K, A61K2039/505, A61K2039/507, A61K38/1709, A61K39/3955